Prestigious annual pediatric medical device competition reveals five finalists
Five finalists have been named in the prestigious annual “Make Your Medical Device Pitch for Kids!” competition presented by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI). Representing innovations in electrophysiology devices that treat congenital heart disease (CHD) and arrhythmias in pediatric patients, these five finalists now have access to a pediatric accelerator program led by MedTech Innovator and will compete for a share of $150,000 in grant funding from the U.S. Food and Drug Administration (FDA) in the final virtual pitch event in September. The pediatric pitch event is part of the 9th Annual Symposium on Pediatric Device Innovation, co-located with the MedTech Conference, powered by AdvaMed.
NCC-PDI is one of five consortia in the FDA’s Pediatric Device Consortia Grant Program created to support the development and commercialization of medical devices for children, which lags significantly behind the progress of adult medical devices. NCC-PDI is led by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Hospital and the A. James Clark School of Engineering at the University of Maryland, with support from partners MedTech Innovator, BioHealth Innovation and design firm Archimedic.
“Experts have indicated there is a critical need for pediatric devices to address arrhythmias in children and we are delighted help advance innovations that seek to bridge that care gap,” says Kolaleh Eskandanian, Ph.D., M.B.A, P.M.P, vice president and chief innovation officer at Children’s National Hospital and principal investigator of NCC-PDI. “For too long, pediatric innovation has lagged behind that of adults. That’s why NCC-PDI remains committed to identifying and supporting technologies that significantly improve pediatric care and are most viable for clinical use and commercialization.”
The following are the five pediatric device innovations that judges selected for the final competition:
- The Children’s Hospital at Montefiore – New York, NY – PeriTorq, a catheter grip tool for use during pediatric cardiac interventional procedures;
- Inkspace Imaging – Pleasanton, CA – a pediatric cardiac and vascular MRI coil;
- Karios Technologies – Charlottesville, VA – Tissue Shield, a technology to prevent scar tissue formation (adhesions) on the heart after surgery;
- Sibel – Niles, IL – ANNE One, ICU-grade wireless sensors for cardiopulmonary monitoring in neonates with congenital heart defects;
- Starlight Cardiovascular – San Diego, CA – Project Lifeline, a less-invasive way to maintain sufficient circulation in newborns with ductal-dependent circulation that increases safety, procedural success and ease of use.
Beginning in June, the five finalists will participate in a pediatric-focused track of the MedTech Innovator accelerator, the world’s largest accelerator of medical devices.
“MedTech Innovator focuses on improving the lives of patients through accelerating the growth of innovative health care solutions,” said Paul Grand, CEO of MedTech Innovator. “We welcome the opportunity to work with this year’s cohort of emerging companies and look forward to providing them with individualized mentorship. Our goal is to help them strategically take the next steps towards product commercialization, as there is an immense need for more medical devices created specifically for children.”
To date, NCC-PDI has mentored over 160 medical device sponsors to help advance their pediatric innovations, with 12 devices having received either their FDA market clearance or CE marking.The accelerator program is the consortium’s latest addition to a network of resources and experts that it provides in support of pediatric innovators.
Eskandanian says supporting the progress of pediatric innovators is a key focus of the new Children’s National Research & Innovation Campus, a first-of-its-kind focused on pediatric health care innovation, with the first phase currently open on the former Walter Reed Army Medical Center campus in Washington, D.C. With its proximity to federal research institutions and agencies, universities, academic research centers, as well as on-site incubator Johnson and Johnson Innovation – JLABS, the campus provides a rich ecosystem of public and private partners which, like the NCC-PDI network, will help bolster pediatric innovation and commercialization.
Media contact: Samantha Desmond | 713-524-8170
About Children’s National Hospital
Children’s National Hospital, based in Washington, D.C., celebrates 150 years of pediatric care, research and commitment to community. Volunteers opened the hospital in 1870 with 12 beds for children displaced after the Civil War. Today, 150 years stronger, it is among the nation’s top 10 children’s hospitals. It is ranked No.1 for newborn care for the fourth straight year and ranked in all specialties evaluated by U.S. News & World Report. Children’s National is transforming pediatric medicine for all children. In 2021, the Children’s National Research & Innovation Campus will open, the first in the nation dedicated to pediatric research. Children’s National has been designated three times in a row as a Magnet® hospital, demonstrating the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty care locations in the D.C. metropolitan area, including the Maryland and Northern Virginia suburbs. Children’s National is home to the Children’s National Research Institute and Sheikh Zayed Institute for Pediatric Surgical Innovation and is the nation’s seventh-highest NIH-funded children’s hospital. It is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels.
Latest posts by BioBuzz Media (see all)
- Adaptive Phage Therapeutics Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, to Chief Medical Officer - July 30, 2021
- Delaware allocates additional $10M for Ready-to-Go Lab Space Grants - July 29, 2021
- Mason’s Michael Buschmann and team at start-up AexeRNA Therapeutics Inc. pursue patents for improved COVID-19 vaccines - July 29, 2021
- Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility - July 29, 2021
- MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market - July 29, 2021